
UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSD
To date, the conceptual framework for this treatment has not been described in the scientific literature. This omission has contributed to misunderstandings about both the theoretical underpinnings of this modality and the therapeutic approach that emerges from it. This paper delineates the psychotherapeutic concepts, theories, and historical antecedents underlying the inner-directed approach to MDMA-Assisted Therapy for PTSD.
Clinically relevant acute subjective effects of psychedelics beyond mystical experience
We suggest actionable recommendations for how the field can transcend current conceptualizations and provide guidance on best practices until the next generation of measures is validated.
Considering distinct positive emotions in psychedelic science
In this review, we discuss psychedelics’ acute subjective and persisting therapeutic effects, outline the science of positive emotions, and highlight the value in considering distinct positive emotions in psychedelic science.
Fragile promise of psychedelics in psychiatry
The US clinical market for ketamine, estimated at $3.1bn in 2022 and expected to expand at 10.6% a year until 2030, is just one of many signs of renewed interest in the use of psychedelics to treat psychiatric conditions.
Personal psychedelic experience as a training qualification for facilitators: A thematic analysis of qualitative interviews with psilocybin experts
Novel state-legal psychedelic paradigms create a real-world opportunity to assess associations between facilitators’ personal psychedelic experience and the safety and outcomes of psychedelic services.
Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals
As psychedelics continue to garner popular and scientific interest, results indicate a pressing need for additional formal training to provide balanced, evidence-based information from trusted sources.
What should constitute a control condition in psychedelic drug trials?
When appropriate control conditions are lacking, it becomes difficult to disentangle placebo and expectation effects from medication effects. Here we explore the neurobiology of placebo and expectation effects, alongside the methodological considerations for selecting suitable control conditions in psychedelic trials.
Healing, spiritual purposes drive many veterans’ use of psychedelics
Most U.S. military veterans who have used psychedelics reported in a recent study that they pursued the substances for healing or spiritual exploration, and over 80% said they benefited from the experience – even those who had challenging outcomes.
Going underground: Demographics, services, and best practices endorsed by practitioners providing support for naturalistic psychedelic use
Although some people report naturalistic psychedelic use with so-called “underground” practitioners, little is known about PAT that occurs outside of controlled clinical settings or perspectives of these practitioners.
Global trends in psychedelic microdosing: Demographics, substance testing behavior, and patterns of use
Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described the characteristics, motivations and practices of microdosers, the differences between individuals that only microdose and those that use both micro and macrodoses of psychedelics remain unexplored.
Santo Daime's MeToo moment - A law suit in Brazil, decades of earlier incidents, and wider questions about safety in psychedelic churches
Basically, the MeToo movement is belatedly catching up with the Daime world. Paulo Roberto is not the only male leader or member of a Daime church being outed as a predator. We are collectively in a moment of reckoning that has been a long time in coming. Goldman tells me expects more cases of misconduct in Daime churches to emerge.
What will a Trump administration do with psychedelics?
As Donald Trump prepares to take office in January, psychedelics are likely to remain a popular issue among members of his inner circle.
An early economic analysis of medical cannabis for the treatment of chronic pain
These findings highlight the substantial cost saving that CBMPs may represent for the treatment of chronic pain patients, and the benefits for healthcare providers as a treatment for this often hard-to-treat population.
Psychedelics vs. traditional treatments — how do they stack up for mental health disorders? – Part 1
This review examines the distinct mechanisms, therapeutic potentials, and limitations of both conventional and psychedelic-assisted treatments, providing a comprehensive analysis of their roles in modern psychiatric care.
Nausea, lion's breath, and ondansetron
Nausea is one of the most common and unpleasant sensations associated with use of almost all psychedelic agents. In this video and written blog post I share my perspective on the occurrence of nausea with psychedelic, strategies that persons could use to manage nausea, and somatic techniques and mindful visualizations to potentially deepen therapeutic benefits or provide an avenue for cathartic experience.
Integrating psychedelic coursework into higher education: A toolkit for academic leaders
This free guide aims to "help educators and academic leaders introduce didactic psychedelic therapy coursework into their programs. Whether you’re looking for ways to start the conversation with colleagues, seeking resources, or simply looking to build a teaching cohort, this introductory toolkit has everything you need to get started.
Talking to your patients about psychedelics: Using an informed approach and understanding indications, risks, and benefits
Have you ever wondered what you should say to a patient who asks whether they should try a psychedelic? ... If you have, the following case vignette and discussion should prove useful.
Expert recommendations for Germany’s integration of psychedelic-assisted therapy
This paper focuses on the development of robust infrastructure in Germany, which will support the roll out of PAT, and details ethical considerations, training protocols, and governmental roles in the formulation of treatment frameworks. This approach aims not only to guide Germany in adopting PAT but also to influence broader European policy, ensuring that patients receive ethically sound and proficient care. The findings suggest pathways for Europe to reclaim its historical lead in psychiatric and therapeutic innovation.
Acceptance as a possible link between past psychedelic experiences and psychological flexibility
These results suggest that the quality and depth of the psychedelic experience, rather than the frequency of use, are primarily linked to psychological flexibility, particularly Acceptance, and overall well-being.
Human brain changes after first psilocybin use
Anatomical and functional brain changes were detected from one-hour to one-month after a single high-dose (25 mg) of psilocybin. Increases in cognitive flexibility, psychological insight, and well-being were seen at one-month.